


FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/662,906	ATTY. DOCKET NO.: A0871.70001US00
		FILING DATE: September 15, 2003	CONFIRMATION NO.: 1268
		APPLICANT: Rong-Hwa Lin et al.	
		GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	1	of	4

### U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
PL	A1	5,378,464		McEver	01-03-1995
	A2	5,618,785		Heavner et al.	04-08-1997
	A3	5,709,859		Aruffo et al.	01-20-1998
	A4	5,710,123		Heavner et al.	01-20-1998
	A5	5,808,025		Tedder et al.	09-15-1998
	A6	5,827,817		Larsen et al.	10-27-1998
	A7	5,834,425		Tedder et al.	11-10-1998
	A8	5,840,679		Larsen et al.	11-24-1998
	A9	5,843,707		Larsen et al.	12-01-1998
	A10	5,852,175		Cummings et al.	12-22-1998
	A11	5,972,625		Rosen et al.	10-26-1999
	A12	6,056,956		Cobbold et al.	05-02-2000
	A13	6,124,267		McEver et al.	09-26-2000
	A14	6,309,639		Cummings et al.	10-30-2001
PL	A15	2002-0164336	A1	Harrison et al.	11-07-2002
	A16	6,667,036		Cummings et al.	12-23-2003

### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
PL	*B1	WO	97/06176		Board of Regents of Univ. of Oklahoma	02-20-1997	
	*B2	WO	00/25808	A1	Genetics Institute, Inc.	05-11-2000	
	B3	WO	03/013603	A1	AbGenomics Corp.	02-20-2003	

EXAMINER: 	DATE CONSIDERED: 11/26/07
--	------------------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/051,497, filed 01/18/2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/662,906	ATTY. DOCKET NO.: A0871.70001US00
		FILING DATE: September 15, 2003	CONFIRMATION NO.: 1268
		APPLICANT: Rong-Hwa Lin et al.	
		GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	2	of	4

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
PG	*C1	BATTISTINI, et al. "CD8+ T cells from 1-37 patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1." <i>Blood</i> , Vol. 101, No. 12, 4775-4782 (June 15, 2003).	
	*C2	BECKWITH et al., "The Protein Product of the Proto-oncogene c-cbl Forms a Complex With Phosphatidylinositol 3-Kinase p85 and CID 19 in Anti-IgM Stimulated Human B-Lymphoma Cells," <i>Blood</i> 88(9):3502-3507, (1996).	
	*C3	BESNAULT et al., "B Cell Receptor Cross-Linking Triggers a Caspase-8-Dependent Apoptotic Pathway That Is Independent of the Death Effector Domain of Fas-Associated Death Domain Protein," <i>J. Immunol.</i> , 167:733-740, (2001).	
	*C4	BORGES et al., "P-Selectin Glycoprotein Ligand-1 (PSGL-1) on T Helper 1 but Not on T Helper 2 Cells Binds to P-Selectin and Supports Migration into Inflamed Skin," <i>J. Exp. Med.</i> 185(3):573-578 (February 3, 1997).	
	*C5	BORGES et al., "The Binding of T Cell-expressed P-selectin Glycoprotein Ligand-1 to E- and P-selectin Is Differentially Regulated," <i>J. Biol. Chem.</i> 272(45):28786-28792 (November 7, 1997).	
	*C6	DIACOVO, et al. "Interactions of human alpha/beta and gamma/delta T lymphocyte subsets in shear flow with E-selectin and P-selectin." <i>J. Exp. Med.</i> , Vol. 183, 1193-1203 (March 1996).	
	*C7	DIMITROFF, et al. "Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: Implications in modulating lymphocyte migration to skin." <i>Blood</i> , Vol. 101, No. 2, 602-610 (January 15, 2003).	
	*C8	EVANGELISTA et al., "Platelet/Polymorphonuclear Leukocyte Interaction: P-Selectin Triggers Protein-Tyrosine Phosphorylation-Dependent CD11b/CD 18 Adhesion: Role of PSGL-1 as a Signaling Molecule," <i>Blood</i> 93(3):876-885 (February 1, 1999).	
	*C9	FARADAY et al., "Leukocytes Can Enhance Platelet-mediated Aggregation and Thromboxane Release via Interaction of P-selectin Glycoprotein Ligand 1 with P-selectin," <i>Anesthesiology</i> 94(1):145-151 (January 2001).	
	*C10	FRENETTE et al., "P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is Expressed on Platelets and Can Mediate Platelet-Endothelial Interactions In Vivo," <i>J. Exp. Med.</i> 191(8):1413-1422 (April 17, 2000).	
	*C11	FUHLBRIGGE et al., "Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells," <i>Nature</i> 389:978-981 (October 1997).	
	C12	HERRON MJ et al., Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1. <i>Science</i> . 2000 Jun 2;288(5471):1653-6.	
PG	*C13	HIRATA et al., "P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is a Physiological Ligand for E-Selectin in Mediating T Helper 1 Lymphocyte Migration," <i>J. Exp. Med.</i> 192(11):1669-1675 (December 4, 2000).	

EXAMINER:	DATE CONSIDERED:
Phillip Gambel	11/26/03

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/051,497, filed 01/18/2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE — No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/662,906	ATTY. DOCKET NO.: A0871.70001US00
		FILING DATE: September 15, 2003	CONFIRMATION NO.: 1268
		APPLICANT: Rong-Hwa Lin et al.	
		GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	3	of	4

<i>mb</i>	*C14	HIROSE et al., "A functional epitope on P-selectin that supports binding of P-selectin to P-selectin glycoprotein ligand-1 but not to sialyl Lewis X oligosaccharides," <i>Internatl. Immunol.</i> 10(5):639-649 (January 26, 1998).	
	*C15	IGARASHI et al., "Telomerase Activity Is Induced in Human Peripheral B Lymphocytes by the Stimulation to Antigen Receptor," <i>Blood</i> , 89(4):1299-1307, (1997).	
	*C16	KAYTES, et al. "P-selectin mediates 1-37 adhesion of the human melanoma cell line NKI-4: Identification of glycoprotein ligands." <i>Biochemistry</i> , Vol. 37, No. 29, 10514-10521 (July 21, 1998).	
	*C17	KIEFFER, et al. "Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: Cutaneous lymphocyte antigen." <i>Biochem. Biophys. Res. Comm.</i> , Vol. 285, No. 3, 577-587 (July 20, 2001).	
	*C18	LASZIK et al., "P-Selectin Glycoprotein Ligand-1 Is Broadly Expressed in Cells of Myeloid, Lymphoid, and Dendritic Lineage and in Some Nonhematopoietic Cells," <i>Blood</i> 88(8):3010-3021 (October 15, 1996).	
	*C19	LEVESQUE et al., "PSGL-1-Mediated Adhesion of Human Hematopoietic Progenitors to P-Selectin Results in Suppression of Hematopoiesis," <i>Immunity</i> 11:369-378 (September, 1999).	
	C20	LI et al., "Visualization of P-Selectin Glycoprotein Ligand-1 As A Highly Extended Molecule and Mapping of Protein Epitopes for Monoclonal Antibodies," <i>J. Biol.Chem.</i> 271(11):6342-6348 (1996).	
	C21	MOORE et al., "P-Selectin Glycoprotein Ligand-1 Mediates Rolling of Human Neutrophils on P-Selectin," <i>J. Cell Biol.</i> 128(4):661-671 (1995).	
	C22	SAKO D et al., Expression cloning of a functional glycoprotein ligand for P-selectin. <i>Cell</i> . 1993 Dec 17;75(6):1179-86.	
	*C23	SHAN et al., "Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies," <i>Blood</i> , 91(5):1644-1652, (1998)	
	*C24	SNAPP et al., "A Novel P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Recognizes an Epitope Within the Tyrosine Sulfate Motif of Human PSGL-1 and Blocks Recognition of Both P- and L-Selectin," <i>Blood</i> 91(1):154-164 (January 1, 1998).	
	*C25	STOCKMEYER et al., "Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells," <i>J. Immunol.</i> , 171:5124-5129, (2003).	
	C26	TREMBLEAU, et al., "Pancreas-Infiltrating Th1 Cells and Diabetes Develop in IL-12 Deficient Nonobese Diabetic Mice," <i>J. Immunol.</i> 163:2960-2968 (1999).	
	C27	VACHINO G et al., P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. <i>J Biol Chem.</i> 1995 Sep 15;270(37):21966-74.	
	C28	VELDMAN GM et al., Genomic organization and chromosomal localization of the gene encoding human P-selectin glycoprotein ligand. <i>J Biol Chem.</i> 1995 Jul 7;270(27):16470-5.	
<i>mb</i>	*C29	WING et al., "Mechanism of First-Dose Cytokine-Release Syndrome by CAMPATH 1-H: Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK Cells," <i>J. Clin. Invest.</i> 98(12):2819-2826 (1996).	



EXAMINER:	DATE CONSIDERED:
<i>Phillip Gambel</i>	<i>11/16/03</i>



\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/051,497, filed 01/18/2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/662,906	ATTY. DOCKET NO.: A0871.70001US00
		FILING DATE: September 15, 2003	CONFIRMATION NO.: 1268
		APPLICANT: Rong-Hwa Lin et al.	
		GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	4	of	4


	*C30	WOLTMANN, et al. "Interleukin-13 induces PSGL-1/P-selectin-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow." <i>Blood</i> , Vol. 95, No. 10, 3146-3152 (May 15, 2000).	
	C31	WU et al., "Role of P-Selectin and Anti-P-Selectin Monoclonal Antibody in Apoptosis During Hepatic/Renal Ischemia Reperfusion Injury," <i>World J. Gastroentero</i> 6(2):244-247 (2000).	
	C32	YAGO et al., "IL-12 Promotes the Adhesion of NK Cells to Endothelial Selectins Under Flow Conditions," <i>J. Immunol.</i> 161:1140-1145 (1998).	
	*C33	YANG et al., "Targeted Gene Disruption Demonstrates That P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is Required for P-Selectin-mediated but Not E-Selectin-mediated Neutrophil Rolling and Migration," <i>J. Exp. Med.</i> 190(12):1769-1782 (December 20, 1999).	

EXAMINER: 	DATE CONSIDERED: 
--	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/051,497, filed 01/18/2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]



<b>FORM PTO-1449/A and B (modified PTO/SB/08)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/662,906	ATTY. DOCKET NO.: A0871.70001US00
		FILING DATE: September 15, 2003	CONFIRMATION NO.: 1268
		APPLICANT: Rong-Hwa Lin et al.	
		GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	1	of	1

#### U.S. PATENT DOCUMENTS


Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
<i>h</i>	A17	2004/0002450	A1	Lazarovits et al.	01-01-2004

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>h</i>	*C34	CHEN SC et al., Cross-linking of P-selectin glycoprotein ligand-1 induces death of activated T cells. <i>Blood</i> . 2004 Nov 15;104(10):3233-42. Epub 2004 Jun 15.	
		U.S.P.T.O. Office Action dated 7/31/2006 in Application Serial No. 10/051,497	
		U.S.P.T.O. Office Action dated 4/19/2007 in Application Serial No. 10/051,497	

EXAMINER: 	DATE CONSIDERED: 11/26/07
--	------------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/051497, filed 01-18-2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE — No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]